Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sym023 in advanced solid tumors or lymphomas
NCT03489343Phase 1Completed
- Sponsor
- Symphogen
- Start
- May 2018
- Primary completion
- Jun 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of S095018 in solid tumor and lymphoma (7 arms), sponsored by Symphogen. Primary endpoint: Dose-limiting Toxicities at 28 days. Started May 2018; status: completed.
02
Drugs
S095018
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT03489343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03489343.